Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

Xingyue Wu, Chengcheng Fu, Hongmiao Shen, Hongying You, Yingying Zhai, Jing Wang, Zhi Yan, Shuang Yan, Weiqin Yao, Jiao Lu, Jingjing Shang, Song Jin, Xiaolan Shi, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 7061.

https://doi.org/10.1182/blood-2023-185763

Published: 2023

Journal Articles

Application of cfDNA-NGS Test in MRD Monitoring of Acute Leukemia Patients with CAR-T Cell Therapy

Juncheng Chen, Qingya Cui, Mengyun Li, Zheng Li, De-Pei Wu, Xiaowen Tang, Hongjie Shen

Blood (2023) 142 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2023-186203

Published: 2023

Journal Articles

BCMA CAR-T-Cell Therapy in Combination with Long-Term Pomalidomide Is a Safe and Effective Treatment for Relapsed/Refractory Multiple Myeloma

Yuhan Yan, Yixuan Tu, De-Pei Wu, Xin Li

Blood (2023) 142 (Supplement 1): 2116.

https://doi.org/10.1182/blood-2023-181573

Published: 2023

Journal Articles

Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia

Qian Wu, De-Pei Wu, Suning Chen, Xiaofei Yang, Jingren Zhang, Mengxing Xue, Xueqing Dou, Sheng-Li Xue, Huiying Qiu, Xiaowen Tang, Yue Han, Jianhong Fu, Xuefeng He

Blood (2023) 142 (Supplement 1): 1528.

https://doi.org/10.1182/blood-2023-182749

Published: 2023

Journal Articles

Recombinant Human Thrombopoietin Combined with Thrombopoietin Receptor Agonists Can Facilitate the Recovery of Platelet after Allogeneic HSCT

Meng Cheng, Chong-Sheng Qian, Hai-xia Zhou, Mingzhu Xu, Wen-jie Gong, Aining Sun, De-pei Wu, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 5451.

https://doi.org/10.1182/blood-2023-191091

Published: 2023

Journal Articles

Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study

Jian Zhang, Baoquan Song, Yin Liu, De-Pei Wu, Huiying Qiu

Blood (2023) 142 (Supplement 1): 5947.

https://doi.org/10.1182/blood-2023-182665

Published: 2023

Journal Articles

Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Yan Qiu, Chong-Sheng Qian, Hai-Xia Zhou, Ming-Zhu Xu, Li-Qing Kang, Ai-Ning Sun, De-Pei Wu, Lei Yu, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 3481.

https://doi.org/10.1182/blood-2023-182728

Published: 2023

Journal Articles

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Mingqing Zhu, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6691.

https://doi.org/10.1182/blood-2023-185362

Published: 2023

Journal Articles

Selinexor and Chidamide in Patients with Relapsed/Refractory Acute Myeloid Leukemia Exposed to Venetoclax: A Single-Arm, Phase 2 Study

Jian Zhang, Baoquan Song, Yin Liu, Yanjun Wu, De-Pei Wu, Huiying Qiu

Blood (2023) 142 (Supplement 1): 5950.

https://doi.org/10.1182/blood-2023-185770

Published: 2023

Journal Articles

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

Hongmiao Shen, Chengcheng Fu, Xingyue Wu, Hongying You, Zhi Yan, Weiqin Yao, Jiao Lu, Yingying Zhai, Jing Wang, Xiaolan Shi, Shuang Yan, Jingjing Shang, Song Jin, Lingzhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6743.

https://doi.org/10.1182/blood-2023-185767

Published: 2023

Journal Articles

PGK1 Represents a Therapeutic Target for Pediatric Acute Myeloid Leukemia Via Regulating c-Myc/SLC7A5/mTOR Pathway

Junyan Gao, Yijun Wu, Yuanyuan Tian, De-Pei Wu, Shaoyan Hu

Blood (2023) 142 (Supplement 1): 1373.

https://doi.org/10.1182/blood-2023-185303

Published: 2023

Journal Articles

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Han-Yu Cao, Lu-Lu Chen, Chao-Ling Wan, Xiao-Hui Hu, Bing Wu, Li Yang, Li Wang, Yang Zhang, De-Pei Wu, Hai-Ping Dai, Hao Zhang, Shengli Xue

Blood (2023) 142 (Supplement 1): 1501.

https://doi.org/10.1182/blood-2023-179733

Published: 2023

Journal Articles

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

Zhao Zeng, Chengcheng Fu, Jinlan Pan, Jiao Lu, Jingjing Shang, Zhiyu Zhang, Hongying You, Wanhui Yan, Chunxiao Wu, Qinrong Wang, Qian Wang, Lijun Wen, Song Jin, Lingzhi Yan, Suning Chen, De-pei Wu

Blood (2023) 142 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2023-184504

Published: 2023

Journal Articles

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Xuanqi Cao, Zheng Li, Yanming Zhang, Qingya Cui, Yunju Ma, Mengyun Li, Sifan Chen, Jia Yin, Wei Cui, Jia Chen, Aining Sun, Huiying Qiu, Suning Chen, Zhengming Jin, Xiaming Zhu, De-Pei Wu, Xiaowen Tang

Blood (2023) 142 (Supplement 1): 6959.

https://doi.org/10.1182/blood-2023-185258

Published: 2023

Journal Articles

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Yingying Zhai, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, Shuang Yan, De-pei Wu, Chengcheng Fu

Blood (2023) 142 (Supplement 1): 6739.

https://doi.org/10.1182/blood-2023-185540

Published: 2023

Journal Articles

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Chengcheng Fu, Jing Wang, Lingzhi Yan, Song Jin, Jingjing Shang, Xiaolan Shi, Weiqin Yao, Zhi Yan, De-Pei Wu

Blood (2023) 142 (Supplement 1): 6736.

https://doi.org/10.1182/blood-2023-185263

Published: 2023

Journal Articles

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Yan-yan Li, Hai-xia Zhou, Si-man Huang, Chao-Ling Wan, Ming-zhu Xu, Wen-jie Gong, Chong-Sheng Qian, De-pei Wu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2023-185312

Published: 2023

Journal Articles

Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial

Blood (2022) 140 (Supplement 1): 5543–5545.

https://doi.org/10.1182/blood-2022-162945

Published: 2022

Journal Articles

Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia

Yan Qiu, Chong-Sheng Qian, Hai-Xia Zhou, Ming-Zhu Xu, Li-Qing Kang, Ai-Ning Sun, De-Pei Wu, Lei Yu, Shengli Xue

Blood (2022) 140 (Supplement 1): 10337–10338.

https://doi.org/10.1182/blood-2022-164636

Published: 2022

Journal Articles

Superior Salvage Treatment with Regimen Containing Sorafenib for Relapse of Acute Myeloid Leukemia with FLT3-ITD after Allo-HSCT

Li Xuan, Yu Wang, Jia Chen, Erlie Jiang, Li Gao, Bingyi Wu, MD, Lan Deng, MD PhD, Xinquan Liang, Fen Huang, Zhiping Fan, Xiaowen Tang, Jing Sun, Xi Zhang, Ming-Zhe Han, De-Pei Wu, Xiao Jun Huang, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2018-99-114103

Published: 2018

NARROW

IMWG /ECOG Frailty Score Was a Good Indicator for ASCT Candidate Selection for NDMM in China from a Hcmmd Retrospective Study

Application of cfDNA-NGS Test in MRD Monitoring of Acute Leukemia Patients with CAR-T Cell Therapy

BCMA CAR-T-Cell Therapy in Combination with Long-Term Pomalidomide Is a Safe and Effective Treatment for Relapsed/Refractory Multiple Myeloma

Improved Prevention and Treatment Strategy of Differentiation Syndrome Contribute to Reduce Early Death of Patients with Acute Promyelocytic Leukemia

Recombinant Human Thrombopoietin Combined with Thrombopoietin Receptor Agonists Can Facilitate the Recovery of Platelet after Allogeneic HSCT

Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study

Safety and Efficacy of CD22/ CD19 CAR-T and Auto-HSCT “Sandwich” Strategy As Consolidation Therapy for Ph Negative B Cell Acute Lymphoblastic Leukemia

Efficacy and Safety of Daratumumab in Combination with Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma with Renal Insufficiency in Real-World: A Non-Interventional Prospective Multicenter Observational Study

Selinexor and Chidamide in Patients with Relapsed/Refractory Acute Myeloid Leukemia Exposed to Venetoclax: A Single-Arm, Phase 2 Study

Speckle Tracking Echocardiography for the Diagnosis and Prognosis of Light Chain Cardiac Amyloidosis

PGK1 Represents a Therapeutic Target for Pediatric Acute Myeloid Leukemia Via Regulating c-Myc/SLC7A5/mTOR Pathway

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

CNVs Numbers Scoring System Was a Good Prognostic Risk Stratification for NDMM with Whole Genomic Mapping Array

Chidamide Combined with a Modified Bu-Cy Conditioning Regimen Improves Survival in Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Selinexor, Daratumumab and Dexamethasone for Patients with Multiple Myeloma Previously Treated with Lenalidomide at First Relapse: A Real-World Study

Initial Safety and Efficacy of Daratumumab (DARA) in Combination with Bortezomib, Lenalidomide, and Dexamethasone in the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE-NDMM) Patients with Standard Risk Who Refused to Accept ASCT As First Line in China

Venetoclax, Cladribine and Cytarabine for the Treatment of Relapse/Refractory Acute Lymphoblastic Leukemia: Interim Analysis of a Phase 2 Trial

Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial

Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia

Superior Salvage Treatment with Regimen Containing Sorafenib for Relapse of Acute Myeloid Leukemia with FLT3-ITD after Allo-HSCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only